89bio Statistics
Total Valuation
89bio has a market cap or net worth of $2.31 billion. The enterprise value is $1.79 billion.
| Market Cap | 2.31B |
| Enterprise Value | 1.79B |
Important Dates
The next estimated earnings date is Friday, November 7, 2025, after market close.
| Earnings Date | Nov 7, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
89bio has 155.57 million shares outstanding. The number of shares has increased by 49.45% in one year.
| Current Share Class | 155.57M |
| Shares Outstanding | 155.57M |
| Shares Change (YoY) | +49.45% |
| Shares Change (QoQ) | +7.87% |
| Owned by Insiders (%) | 0.69% |
| Owned by Institutions (%) | 65.70% |
| Float | 101.79M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 4.22 |
| P/TBV Ratio | 4.42 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 15.19, with a Debt / Equity ratio of 0.07.
| Current Ratio | 15.19 |
| Quick Ratio | 14.17 |
| Debt / Equity | 0.07 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -78.17 |
Financial Efficiency
Return on equity (ROE) is -86.86% and return on invested capital (ROIC) is -52.84%.
| Return on Equity (ROE) | -86.86% |
| Return on Assets (ROA) | -49.10% |
| Return on Invested Capital (ROIC) | -52.84% |
| Return on Capital Employed (ROCE) | -82.59% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$4.84M |
| Employee Count | 93 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, 89bio has paid $1.35 million in taxes.
| Income Tax | 1.35M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +81.42% in the last 52 weeks. The beta is 1.22, so 89bio's price volatility has been higher than the market average.
| Beta (5Y) | 1.22 |
| 52-Week Price Change | +81.42% |
| 50-Day Moving Average | 12.52 |
| 200-Day Moving Average | 9.79 |
| Relative Strength Index (RSI) | 76.94 |
| Average Volume (20 Days) | 5,915,993 |
Short Selling Information
The latest short interest is 6.77 million, so 4.35% of the outstanding shares have been sold short.
| Short Interest | 6.77M |
| Short Previous Month | 8.72M |
| Short % of Shares Out | 4.35% |
| Short % of Float | 6.65% |
| Short Ratio (days to cover) | 0.74 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -465.68M |
| Pretax Income | -448.86M |
| Net Income | -450.21M |
| EBITDA | -465.64M |
| EBIT | -465.68M |
| Earnings Per Share (EPS) | -$3.41 |
Balance Sheet
The company has $561.16 million in cash and $37.62 million in debt, giving a net cash position of $523.55 million or $3.37 per share.
| Cash & Cash Equivalents | 561.16M |
| Total Debt | 37.62M |
| Net Cash | 523.55M |
| Net Cash Per Share | $3.37 |
| Equity (Book Value) | 521.73M |
| Book Value Per Share | 3.52 |
| Working Capital | 561.91M |
Cash Flow
In the last 12 months, operating cash flow was -$439.10 million and capital expenditures -$87,000, giving a free cash flow of -$439.19 million.
| Operating Cash Flow | -439.10M |
| Capital Expenditures | -87,000 |
| Free Cash Flow | -439.19M |
| FCF Per Share | -$2.82 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
89bio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -49.45% |
| Shareholder Yield | -49.45% |
| Earnings Yield | -19.50% |
| FCF Yield | -19.02% |
Analyst Forecast
The average price target for 89bio is $22.31, which is 50.34% higher than the current price. The consensus rating is "Buy".
| Price Target | $22.31 |
| Price Target Difference | 50.34% |
| Analyst Consensus | Buy |
| Analyst Count | 11 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |